Trial Profile
A Double Blind Study to Evaluate Effects of Repeat Doses of SB-659032 on Platelet Aggregation in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2023
Price :
$35
*
At a glance
- Drugs Rilapladib (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions; Biomarker
- Sponsors GSK
- 19 Dec 2012 New trial record